Cardiology

Cardiology

By ReachMDMedicine
Download on the App Store

All Cardiology episodes

  • Latest Clinical Trial Outcomes and Breakthroughs for FCS
    Guest: Daniel Gaudet, MD, PhD
    Guest: Pam R. Taub, MD, FACC, FASPC

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • Obesity and Comorbidities: Strategies for Effective Patient Management
    Guest: Michael Crotty, MB, BCh, BAO
    Guest: Ana Maria Cebrián-Cuenca, MD, PhD

    This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

    This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

    5 min
  • Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
    Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
    Host: Rishi Wadhera, MD, MPP, Mphil

    This on-demand knowledge primer explores key challenges and evidence-based strategies for improving atherosclerotic cardiovascular disease (ASCVD) management in rural populations. Led by two expert faculty members, the program provides a comprehensive overview of disparities in ASCVD care, guideline-directed therapies, and practical approaches to overcoming barriers in rural settings. Participants will gain essential knowledge to enhance patient outcomes and optimize cardiovascular care in underserved communities.

    1 hr
  • Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
    Guest: Akshay S. Desai, MD

    These video briefs feature expert insights on the latest clinical data presented at ACC 2025. Leading cardiologists discuss emerging nonsteroidal mineralocorticoid receptor antagonists (MRAs), their efficacy in heart failure management, and their potential advantages over traditional steroidal MRAs. The series explores key trial findings, safety considerations, and clinical implications for optimizing patient care. Viewers will gain practical knowledge on integrating these novel therapies into clinical practice to improve patient outcomes.

    5 min
  • Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
    Host: Harry Yoon, MD
    Host: Jaffer Ajani, MD

    This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

    Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

    5 min
  • The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
    Host: Harry Yoon, MD
    Host: Jaffer Ajani, MD

    This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

    Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

    5 min
  • The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
    Host: Harry Yoon, MD

    This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

    Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

    6 min
  • ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
    Host: Harry Yoon, MD
    Host: Jaffer Ajani, MD

    This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

    Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

    5 min
  • Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
    Host: Harry Yoon, MD
    Host: Jaffer Ajani, MD

    This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

    Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

    5 min
  • Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
    Host: Jaffer Ajani, MD

    This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

    Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.

    6 min